Issue 3, 2002

Aggregation, binding, and dimerisation studies of a teicoplanin aglycone analogue (LY154989)

Abstract

LY154989 is a vancomycin group antibiotic closely related in structure to teicoplanin aglycone. In view of the clinical importance of teicoplanin, the dimerisation, aggregation, and binding of bacterial cell wall analogues by LY154989 are of interest. These properties have been studied by proton NMR spectroscopy. LY154989 has been shown to form concentration-dependent aggregates in aqueous solution, similar to those of teicoplanin, even though it does not possess a C11 acyl chain, which was hitherto thought to be the cause of this aggregation. The aggregation can be disrupted by the addition of bacterial cell wall precursor analogues such as Ac2-KDADA, Ac-DADA or Ac-DA. Thus, growing bacteria may disrupt aggregates of teicoplanin and LY154989. LY154989 dimerises weakly in aqueous solution and the dimerisation is weakly cooperative with ligand binding.

Graphical abstract: Aggregation, binding, and dimerisation studies of a teicoplanin aglycone analogue (LY154989)

Supplementary files

Article information

Article type
Paper
Submitted
12 Sep 2001
Accepted
09 Jan 2002
First published
04 Feb 2002

J. Chem. Soc., Perkin Trans. 2, 2002, 598-603

Aggregation, binding, and dimerisation studies of a teicoplanin aglycone analogue (LY154989)

B. Bardsley, R. Zerella and D. H. Williams, J. Chem. Soc., Perkin Trans. 2, 2002, 598 DOI: 10.1039/B108273F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements